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Bone marrow transplantation in man can cure certain diseases, butis frequently
accompanied by severe graft-versus-host disease (GVHD)' (1). Although GVHD
can be prevented by depleting the marrow inoculum of mature T cells (2),
patients receiving T-depleted marrow cells often show an increased incidence of
graft rejection (reviewed in reference 3). Moreover, in leukemic patients the
incidence of leukemic relapse tends to be higher with transfer of T-depleted
marrow cells than with untreated marrow (3). T depletion of marrow cells thus
appears to be a double-edged sword, and some clinicians (e.g., see references 4,
5) doubt whether the benefits of this procedure are sufficient to outweigh the
severe side effects. Although this viewpoint is tenable in the case of HLA-
compatible marrow transplants, i.e., where GVHD if often nonfatal, patients
given HLA-incompatible marrow followed by conventional immunotherapy gen-
erally die from GVHD unless the marrowis T depleted (6). Despite theincreased
risk of graft rejection, T depletion of the marrow thus appears to be near
mandatory for patients given HLA-incompatible marrow.
In considering methods for improving the success rate of HLA-mismatched
marrow transplantation, an obvious issue is whether the marrow has to be
depleted of both T cell subsets, i.e., of both CD4+ and CD8+ cells, or of only
one subset. Although the relative importance ofCD4' and CD8' cells in GVHD
has been debated fora number ofyears (reviewed in reference 7), recent studies
in mice conditioned with heavy irradiation have shown that each T cell subset
can cause lethal GVHD in H-2-incompatible recipients (7-9). Based on studies
with mutant strains of mice expressing slight (1-3 amino acid) differences in
class I or class II H-2 molecules, it has been found that lethal GVHD directed to
class I differences is controlled almost exclusively by CD8+ (Lyt-2'}) cells, whereas
CD4+ (L3T4') cells account for GVHD to class II differences (10). Similar
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'Abbreviationsused in thispaper:
￿
BM,bone marrow;GVHD, graft-versus-host disease; LN,lymph
node; MST, mean survival time; STx, sham thymectomized; Tx, thymectomized.
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stringent specificity of Lyt-2' and L3T' cells for class I and class II molecules,
respectively, applies in a variety of other assay systems including the mixed
lymphocyte reaction (11) and skin allograft rejection (10, 12).
Despite the evidence that L3T4' and Lyt-2' cells both participate in GVHD
(implying that human marrow should be depleted of both subsets), the issue of
whether the two T cell subsets cause the same or different patterns of disease
has not received close attention. In particular, very little is known about the
features of the lethal form of GVHD seen in heavily irradiated mice. Rolink et
al. (13, 14) reported that L3T4'' and Lyt-2' cells elicited different patterns of
GVHD in nonirradiated recipients, but GVHD in this situation was generally
nonlethal.
The main aim ofthe experiments in this paper was to seek detailed information
on the capacity of Lyt-2' cells to mediate lethal GVHD in class I-different
irradiated mice and, in particular, to assess whether GVHD mediated by Lyt-2'
cells depends on help from L3T4+ cells. The results suggest that Lyt-2' cells do
mediate GVHD in the apparent absence of L3T4+ cells, although under certain
conditions the potency of Lyt-2' cells can be considerably enhanced by addition
of small doses of L3T4+ cells or their products (IL-2). Paradoxically, large doses
of L3T4+ cells do not augment GVHD but instead provide long-term protection.
Materials and Methods
Mice. C57BL/6Kh (B6), B6.C-H-26"'' (bml), B6.C-H-26'" 12 (bm12) and F, hybrids
between these strains were obtained from the breeding colony at the Research Institute
of Scripps Clinic (SCRF). All experiments were performed at SCRF. Male mice were used
in most experiments.
Irradiation.
￿
Mice were exposed to a single dose of whole body 'Y-[ 1s7Cs] irradiation at
90 rad/min via a Gamma Cell 40 irradiator (Atomic Energy of Canada, Ottawa, Canada).
Media.
￿
As described elsewhere (11), RPMI 1640 or HBSS supplemented with either
5% FCS or gamma globulin-depleted horse serum were used.
Monoclonal Antibodies.
￿
Anti-L3T4 (GK1 .5 or RL172, ascites fluid), anti-Lyt-2 (3.168,
ascites fluid), anti-Thy-1 .2 (Jlj, ascites fluid) and anti-B (J1 Id, culture supernatant) and
guinea pig serum as a source of C' were used as described previously (11).
Purification of T Cell Subsets.
￿
As described in detail elsewhere (11), -99% purified T
cell subsets were obtained by subjecting pooled lymph node (LN) cells to mAb + C'
followed by positive panning on mAb-coated dishes. For example, Lyt-2+ cells were made
by (a) treating LN cells with anti-L3T4 + anti-B (J11d) mAb + C followed by (b) positive
panning on anti-Lyt-2 mAb-coated plates.
GVHassay.
￿
Mice aged 3-10 mo were irradiated 1 d before transfer of lymphoid cells
(injected intravenously) and were given standard food and water ad libitum without
antibiotics. Mice were examined three to four times/week (usually daily for the first 3-4
wk) for 100 d or until death. Mice judged to be moribund, i.e., unable to take food or
water, were killed.
Thymectomy.
￿
Mice aged 6-8 wk were thymectomized or sham thymectomized by the
method of Miller (15).
rIL-2.
￿
Preparations of rIL-2 and mock rIL-2 were kindly provided by Cetus Corp.
(Emeryville, CA) and were kept frozen until the day of use. Preparations were diluted in
HBSS and given intraperitoneally in a volume of 0.2 ml.
Median Survival Time (MST).
￿
MSTs were calculated as described previously (8).
Results
In all of the experiments presented below, mice were exposed to irradiation 1
d before transfer of lymphoid cells. Unless stated otherwise, Lyt-2' and L3T4+558
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TABLE I
Mortality in Heavily Irradiated (1,000 rad) (B6 X bml)F, Mice Injected
with Bd BM and Varying Doses ofB6 Lyt-2+ Cells
Mortality
T cells
￿
T cells
￿
Ex
￿
Deaths
Mice given whole body irradiation 1 dbefore were injected intravenously with
highly purified B6 Lyt-2+ or L3T4+ cells mixed with a uniform dose of 2 X
106 anti-Thy-1 + C-treated B6 BM. The recipients were inspected three to
four times per week until death or for 100 d. The data were compiled from
11 different experiments, each experiment involving at least four mice per
group.
* The surviving mice in these groups allshowed prominentsymptoms of chronic
GVHD during the first 2 mo but then partially recovered; two mice subse-
quently died after 100 d.
cells were purified from LN cells by a combination of mAb + C treatment
followed by positive panning (Materials and Methods). In most experiments, T
cells were coinjected with donor-type marrow cells; marrow cells were pretreated
with anti-Thy-1 mAb + C and injected in a dose of 2 X 106 cells/mouse. All cell
suspensions were given intravenously. To avoid the problem of host-versus-graft
reactions, parental strain T cells were transferred to F, hybrid mice.
Dose ofLyt-2+ Cells Required to Induce Lethal GVHD in Class I-different Recipi-
ents. In previous studies (10), lethal GVHD developing in class I-different
homozygous bm 1 recipients of B6 Lyt-2+ cells was examined with relatively high
doses of Lyt-2+ cells (1 .5-7.5 X 106) and with heavy irradiation of the host (1,000
rad). The pooled results of 11 different experiments in which varying doses of
B6 Lyt-2+ cells were transferred with B6 BM to heavily irradiated (1,000 rad)
heterozygous (B6 X bm 1)F, mice are shown in Table I. Two main points arise
from the data. First, mortality rates approaching 100% were observed over a
200-fold range in the dose of Lyt-2+ cells; 105 cells caused severe mortality and
even as few as 104 cells caused 50% mortality. Second, irrespective of the dose
transferred
with B6 BM transferred
n
ments
eri-
n
Dead/
total Dead
%
MST
d
occur-
ring
before
21d
B6 Lyt-2+ 2 x 10' 1 5/5 100 38 20
1 x 10' 2 16/16 100 33 19
5 x 106 2 11/13 85* 37 23
3 x 106 5 33/34 97* 37 18
2 x 106 3 19/19 100 39 0
1 x 106 3 22/22 100 35 0
3 x 105 3 22/22 100 35 0
1 x 105 2 14/16 88* 52 0
1 x 10, 1 4/8 50* 87 0
B6 L3T4+ 1 x 10' 2 0/12 0 >100 0
3 x 106 4 1/22 5 >100 100
1 x 106 5 1/25 4 >100 0
B6 BM only - 11 3/60 5 >100 67E
r
3
30
25
20
150
8 16 24 32 40
Time Post-Reconstitution (days)
SPRENT ET AL .
￿
559
FIGURE 1 . Mortality rates in heavily irradiated
(1,000 rad) (B6 X bml)F l mice given high vs . low
doses of B6 Lyt-2' cells plus a constant dose of 2
X 106 T-depleted B6 BM (eight mice/group) ; Lyt-
2' cells were injected in a dose of 10' cells (m)
(MST = 49 d) or 10 5 cells (111) (MST = 54 d) per
mouse. Control mice received irradiation and
BM without Lyt-2' cells (five mice/group) . Data
are from a single experiment .
FIGURE 2 .
￿
Mean body weights of heavily irradi-
ated (1,000 rad) (B6 X bm 1)F, mice given a mix-
ture of 2 X 106 Lyt-2' cells plus B6 BM or B6 BM
alone (five mice/group) . The recipients were
weighed every 2 d for 40 d or until death (arrows) ;
the control mice survived for >100 d . In the
particular experiment shown, the recipients of B6
Lyt-2' cells plus B6 BM became ill, with hunched
posture and ruffled fur at day 6 . The clinical
condition of the mice improved after day 12 but
deteriorated again at about day 24 . Thereafter the
conditionof the mice worsened progressively until
death .
of Lyt-2+ cells injected, most of the recipients died from chronic GVHD, death
rates in recipients of high (107) vs . low (105) doses of cells being remarkably
similar (Fig. 1) . Especially with high doses of Lyt-2' cells, the recipients became
obviously ill at the end of the first week after transfer and showed weight loss
and ruffled fur . Although a few mice deteriorated further and died over the
next 2 wk (not seen with lower cell doses ; Table I), most of the mice showed a
temporary recovery ; although weight gain was marginal (Fig . 2), ruffled fur
became much less prominent at the end of the second week and the mice
regained near-normal physical activity . At ^-4 wk after transfer, the mice showed
a sudden recrudescence ofsymptoms . The mice developed severe and progressive
weight loss with diarrhea and hunched posture and most mice died over the next
1-2 wk ; weight loss at the time of death was often extreme (>40%) (Fig. 2) .
In accordance with previous findings (10), transfer of B6 L3T4' cells to
irradiated class 1-different (B6 X bml)F l mice caused no mortality (Table I) or
signs of ill health .
GVHD in Lightly Irradiated Recipients .
￿
As illustrated in Table 11, varying the
dose of irradiation given to (B6 X bml)F1 recipients of B6 Lyt-2' cells had
surprisingly little effect on the severity ofGVHD . Thus, over a 20-fold range in560 GRAFT-VERSUS-HOST DISEASE MEDIATED BY Lyt-2+ CELLS
TABLE II
Mortality in Irradiated (B6 X bml)F, Recipients ofB6 Lyt-2' Cells
and B6 BM: Effect of Varying the Dose ofIrradiation
Data arefrom a single experiment.
TABLE III
Rapid Mortality in Heavily Irradiated (1,000 rad) (B6 X bml)F,
Mice Given B6 Lyt-2' Cells plus F, Host BM
Each BM population was injected with adose of 2 X 106 cells,
the dose of Lyt-2' cells, mortality rates were as severe in 600 rad irradiated
recipients as in mice given 1,000 rad, and the MSTs showed little variation.
Influence of Donor-vs.-Host BM Cells.
￿
In all of the above experiments, Lyt-2'
cells were transferred with syngeneic (B6) BM. When B6 Lyt-2' cells were
transferred with host-type (F,) BM to heavily irradiated (1,000 rad) recipients,
all of the mice died within 2 wk (Table III). At death, the mice showed extreme
tissue pallor and marked atrophy of the spleen, implying that death resulted
from hematopoietic failure. Coinjecting B6 Lyt-2' cells with a mixture ofdonor
and host marrow led to the typical pattern of chronic GVHD seen with transfer
of donor marrow (Table III). This latter finding suggested that the donor Lyt-
2' cells destroyed F, BM cells by direct cell contact rather than via a bystander
effect.
Striking evidence on the capacity of donor Lyt-2' cells to destroy host-type
hematopoietic cells is illustrated by the experiments shown in Table IV in which
B6 Lyt-2' cells
transferred with
B6 BM
n
Dose of irra-
diation given
to recipients
rad
Dead/total
Mortality
Mortality
%
MST
d
5 X 106 1,000 6/8 75 43
800 8/8 100 37
600 8/8 100 33
2.5 X 105 1,000 8/8 100 33
800 8/8 100 32
600 8/8 100 33
BM only 1,000 0/5 0 >100
800 0/5 0 >100
600 0/5 0 >100
Cells transferred to (B6 X bmI)F,
mice given 1,000 rad Dead/
total
Mortality
Mortality
%
MST
d
106 B6 Lyt-2+ + B6 FM 8/8 100 43
106 B6 Lyt-2+ + F, BM 8/8 100 12
106 B6 Lyt-2' + B6 BM + F, BM 8/8 100 47
B6 BM only 0/5 0 >100
F, BM only 0/5 0 >100
B6 + F, BM 0/5 0 >100SPRENT ET AL.
TABLE IV
RapidMortality in Lightly Irradiated (500 rad) (B6 x bml)Fl Mice
GivenB6 Lyt-2' Cells withoutMarrow Cells
* Of the six mice surviving >100 d, four mice died over the next 6 wk
with typical symptoms of chronicGVHD.
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B6 Lyt-2+ cells were transferred to lightly irradiated (500 rad) (B6 X bml)F1
recipients ± donor-type BM. When 2 X 106 B6 Lyt-2+ cells were transferred to
500 rad recipients with B6 BM, the recipients all died from chronic GVHD .
However, when the Lyt-2' cells were transferred without BM cells, the mice
suddenly died at 2 wk after transfer from hematopoietic failure associated with
marked anemia and striking lymphoid atrophy. This finding was only observed
with relatively high doses of cells (2 X 106); lower doses (105) produced chronic
GVHD. No mortality was seen in control mice given 500 rad without Lyt-2'
cells.
Are Lyt-2' Cells Helper Independent In Vivo?
￿
The conspicuous potency of Lyt-
2' cells at causing lethal GVHD to class I differences raised the question whether
Lyt-2' cells function autonomously in vivo or depend on minor degrees of help
provided by L3T4+ cells. Two approaches were used to address this question.
Thymectomy of the Host.
￿
It was mentioned earlier that recipients of class I-
different Lyt,2+ cells plus donor BM typically showed a sudden, lethal exacer-
bation of symptoms at about 4 wk after transfer. It seemed possible that this
pattern of disease reflected bystander help provided by newly formed donor-
derived L3T4+ cells arising in the host thymus. This possibility was investigated
by studying GVHD in thymectomized (Tx) recipients. Table V shows results
compiled from five different experiments in which B6 Lyt-2+ cells plus B6 BM
were transferred to heavily irradiated Tx (B6 X bml)F1 mice; sham-thymecto-
mized (STx) mice were used as controls. Heavy mortality occurred in both
groups of mice: MSTs appeared to be slightly prolonged in ATx recipients but
this difference was not statistically significant. A small proportion of the recipients
survived for >100 d in both groups, but these mice all showed evidence of
chronic GVHD (Table V, footnote) . It is worth mentioning that the mice used
in these experiments were somewhat older than in earlier experiments. Although
we have not done a thorough study of anti-class I GVHD in old-vs.-young mice,
older mice tend to die more slowly, perhaps because of their greater stores of
body fat.
Injection ofAnti-L3T4 mAb.
￿
The second approach for testing whether GVHD
induced by Lyt-2' cells requires help from L3T4+ cells was to transfer B6 Lyt-
2+ cells plus B6 BM to heavily irradiated (B6 X bml)F1 mice and then inject the
Cells transferred to
(B6 x bml)F, mice
given 500 rad
B6
BM
added
Ex-
peri-
ments
n
Dead/total
Mortality
Dead MST
d
2 x 106 B6 Lyt-2+ + 2 10/10 100 32
2 x 106 B6 Lyt-2+ - 4 25/25 100 15
1 x 105 B6 Lyt-2+ - 2 10/16* 63 59
- + 2 0/8 0 >100
- - 2 0/8 0 >100562
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TABLE V
Mortalityin Thymectomized Irradiated (1,000 rad) (B6 X bml)Fl Mice
Given B6 Lyt-2' Cells plus B6 Marrow
Thymec-
tomy
(Tx) or
sham Ex- T cellstransferred
￿
thymec-
with B6 BM
￿
tomy
￿
men
Host mice were used at 4-8 wk after Tx or STx for most experiments and at 9
mo for one experiment. Of the total of seven Tx mice that survived for >100
days, allof thesemice showed symptoms of chronic GVHD and only threeof the
mice survived beyond 150 d; of thethreesurvivors in the STx group, twoof the
mice survived beyond 150d.
recipients repeatedly with large amounts of anti-L3T4 (GK1 .5) mAb (Table VI,
footnote). Control experiments established that a course of anti-L3T4 mAb
injections was highly effective at inhibiting anti-class II GVHD, i.e., GVHD
developing in irradiated (B6 X bm 12)F, recipients ofclass I1-different B6 L3T4'
cells (Table VI, Exp. A, groups 4 and 5). Significantly, injection of anti-L3T4
mAb had little if any effect in prolonging the survival of irradiated (B6 X bm I )F,
mice given class 1-different B6 Lyt-2' cells (Table VI, Exp. A, groups 1 and 2).
Likewise, repeated injection of anti-L3T4 mAb failed to overcome the pattern
of rapid death from hematopoietic failure seen when B6 Lyt-2+ cells were
transferred to (B6 X bml)F, mice with host-type marrow cells (Table VI, Exp.
B, groups 2 and 3).
Effects of Supplementing Lyt-2' Cells with Small Doses of L3T4' Cells or rIL-
2. Although the above two approaches showed little or no evidence that GVHD
mediated by Lyt-2' cells required the presence of L3T4' cells, studies in which
Lyt-2+ cells were supplemented with small doses (5106) of donor-type L3T4'
cells led to a pattern of acute GVHD and early death (Table VII). Interestingly,
this effect was much more prominent with relatively high doses of Lyt-2+ cells
(5 X 106) than with lower doses (2 X 106).
It seemed highly likely that the capacity of small doses of L3T4' cells to
exacerbate GVHD mediated by Lyt-2' cells reflected local release of IL-2. To
s (STx)
of
recipi-
ents
n
Dead/
total Dead
%
Mortality
MST
d
p values
5 x 106 B6 Lyt-2' STx 2 8/8 100 57 >0.1 Tx 2 7/8 88 69
3 x 106 B6 Lyt-2' STx 2 14/16 88 39 >0.1
Tx 3 17/21 81 57
3 x 105 B6 Lyt-2' STx 1 4/5 80 52 >0.1
Tx 1 4/6 67 98
B6 BM only STx 3 0/13 0 >100
Tx 4 1/12 8 >100SPRENT ET AL.
TABLE VI
Mortalityin Irradiated (1,000 rad) (B6 x bml)F, Mice GivenB6 Lyt-2' Cells and
Repeated Injections ofAnti-L3T4mAb
Mice were injected intraperitoneally with undiluted GK1.5 ascites fluid in doses of 0.2 ml/mouse on
days 1, 3, and 7 and then 0.1 ml at weekly intervals thereafter; for (B6 x bm12)F, recipients, the
injections were stopped after 6 wk. Others (16) have demonstrated that GK1 .5 mAb is highly effective
at removing L3T4' cells in vivo. The MSTs in group 1 vs. 2 in Exp. A were not significantly different
(p > 0.1).
TABLE VII
Mortality in Irradiated (1,000 rad) (B6 x bml)F, Mice Given B6 Lyt-2' Cellsplus
B6 Marrow: Effects ofAdding B6 L3T4' Cells
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* For preparing L3T4' cells in large doses, the (tedious) positive panning step was omitted, i.e., LN
cells were pretreated with J1 ld + anti-Lyt-2 mAb + C but were not panned on anti-L3T4 mAb-
coated plates. p values: groups 1 vs. 2, p < 0.02; groups 4 vs. 5, p < 0.02; groups 6 vs. 7, p > 0.1 .
Exp. Group Cells transferred to irra-
diated mice
Irradiated
recipients
Injection of
anti-L3T4
mAb
Dead/
total
Mortality
Dead MST
% d
A 1 1 x 106 B6 Lyt-2' + (B6 x bm 1)F, - 8/8 100 50
B6 BM
2 + 8/8 100 55
3 B6 BM only (B6 x bml)F, - 0/5 0 >100
4 1 x 106 B6 L3T4* + B6 (B6 x bm l2)F, - 8/8 100 10
BM
5 + 1/8 13 >100
6 B6 BM only (B6 x bm12)F, - 0/4 0 >100
B 1 2 x 106 B6 Lyt-2' (B6 x bml)F, - 5/5 100 43
+ B6 BM
2 2 x 106 B6 Lyt-2* + F, (B6 x bm, )F, - 5/5 100 13
BM
3 + 5/5 100 11
4 B6 BM only (B6 x bml)F, - 0/5 0 >100
5 F, BM only (B6 x bml)F, - 0/5 0 >100
Group
Dose of B6
Lyt-2' cells
given with
B6 BM
Dose of B6
L3T4' cells
added to B6
Lyt-2' cells
Experi-
ments
n
Dead/total
Mortality
Dead
%
MST
d
Reduc-
tion of
MST
1 5 x 106 - 3 13/13 100 50
2 1 x 106 3 13/13 100 17 66
3 0.2 x 106 1 5/5 100 16 68
4 3 x 106 - 3 24/24 100 50
5 1 x 106 3 24/24 100 24 52
6 2 x 106 - 2 14/14 100 37
7 1 x 106 2 12/12 100 33 11
8 2 x 106 - 2 13/13 100 40
9 3 x 107* 2 0/10 0564
￿
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FIGURE 3 .
￿
Capacity of rIL-2 to accelerate mor-
tality in heavily irradiated (1,000 rad) (B6 X
bm 1)F, mice given 2 X 10 6 B6 Lyt-2+ cells plus B6
BM (-) . Intraperitoneal injections ofrIL-2 (5,000
U/injection) were given every 2 dfora total of six
injections beginning on day 8 after irradiation
(MST = 29 d, 16 mice) . Control mice received
either : (a) Lyt-2' cells plus B6 BM plus mock rIL-
2 (1110 (MST = 49 d, 16 mice) or (b) B6 BM plus
rIL-2 ( : :) (MST = >100 d, 10 mice) . Pooled data
from two experiments . The accelerated mortality
induced by the rIL-2 injections in recipients of
Lyt-2+ cells was statistically significant (p < 0.02) .
assess this possibility, heavily irradiated (B6 X bm 1)FI mice were given B6 Lyt-
2' cells plus B6 BM and then injected repeatedly with HL-2 (six doses of 5,000
U given every 2 d beginning at 1 wk after T cell transfer) . As shown in Fig . 3,
injection of HL-2 caused the same pattern of accelerated mortality seen with
transfer of small doses of L3T4' cells . Control mice given AL-2 without B6 Lyt-
2' cells showed little or no mortality .
Effect ofSupplementing Lyt-2' Cells with Large Doses ofL3T4' Cells.
￿
Although
the capacity of small doses of L3T4' cells to augment anti-class I GVHD was a
constant finding(provided that Lyt-2' cells were transferred in high doses; Table
VII), transfer of larger doses of L3T4+ cells (2-5 X 106) led to inconsistent
results (data not shown) ; potentiation of GVHD tended to be less prominent
and, paradoxically, some mice showed little or no evidence of GVHD, implying
that higher doses ofL3T4+ cells might be protective . To assess this idea, Lyt-2'
cells were supplemented with comparatively massive doses of L3T4+ cells (3 X
107 cells) . The striking finding, observed in two separate experiments, was that
heavily irradiated (B6 X bml)FI mice given 2 X 106 B6 Lyt-2' cells plus B6 BM
together with a dose of 3 X 107 B6 L3T4+ cells showed no mortality (Table
VII) . Except for weight loss in the first two weeks and a mild retardation in
weight gain thereafter, the mice showed no symptoms ofGVHD .
Effect of Injecting Anti-Thy-I mAb .
￿
The typical pattern of chronic GVHD
mediated by Lyt-2' cells plus syngeneic BM in the absence of L3T4+ cells (e.g .,
Fig. 1) raised the question whether the Lyt-2' cells mounted a prolonged attack
against the host, or conversely, attacked the host for only a brief period, the
consequences of this attack being slow to develop . To seek information on this
question, heavily irradiated (B6 X bm 1)FI recipients of B6 Lyt-2' cells plus B6
BM were given a single injection of anti-Thy-1 mAb at 3 wk after transfer . As
shown in Fig. 4, injection of anti-Thy-1 mAb was clearly protective, although
50% of the recipients eventually died .
Discussion
Because of the expense and long-term nature of GVHD experiments, the
principle aim of the present studies was not to examine GVHD in a wide variety
of class 1-different strain combinations but to seek comprehensive information
on a single combination, i.e ., B6 --* bml . Although some of the data, e.g ., the
protective effect of L3T4' cells, have been confirmed in the reciprocal bml --->
B6 combination (data not shown), detailed information on other combinations isSPRENT ET AL .
￿
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FIGURE 4 . Mortality rates in heavily irradiated
(1,000 rad) (B6 X bm l )F, mice given 2 x 10 6 B6
Lyt-2' cells plus B6 BM followed 21 d later by a
single intraperitoneal injection ofT24anti-Thy-1
mAb (~) (MST = 87 d, 10 mice); T24anti-Thy-1
mAb (0.5 ml of undiluted ascites fluid/mouse) has
known opsonizing activity in vivo (see reference
10) . Control mice received Lyt-2' cells plus BM
without anti-Thy-1 mAb (1111)(MST= 44 d, 9 mice)
or BM cells only (=) (MST >100 d, 8 mice) . The
enhanced survival seen in the recipients of anti-
Thy-l mAbwas statistically significant (p< 0.02) .
not yet available . It should be emphasized that the B6 anti-bm 1 response is
particularly strong (10, 11), and conclusions based on this strain combination
(see below) might not necessarily apply to weaker class I differences . However,
it is worth mentioning that a preliminary study in which purified B6 Lyt-2' cells
were transferred to irradiated bm9 mice led to severe GVHD (Mowat, A ., and
J. Sprent, unpublished data) ; this combination leads to only weak responses in
vitro in the absence ofadded help (11, 17) .
The experiments in this paper indicate that the particular pattern ofGVHD
seen in irradiated (B6 X bml)F, mice given class I-different B6 Lyt-2' cells
depends critically on two factors : (a) the origin (donor vs . host) of the BM cells
used forstem cell reconstitution and (b) thepresence or absence ofdonor-derived
L3T4+ cells .
When Lyt-2' cells were transferred to irradiated class I-different recipients
without BM or with host BM, the mice died rapidly from hematopoietic failure
(Tables III and IV) . Since this syndrome was not observed in mice given a
mixture ofdonor and host BM, hematopoietic failure presumably did not reflect
abystander effect, i.e ., release of toxic lymphokines, butrather direct destruction
of class I-different host stem cells by antigen-specific Lyt-2' cells . In all proba-
bility this form of GVHD (perhaps better termed a graft-vs.-host reaction) is
controlled by classic cytotoxic lymphocytes .
Early deaths were rare when class 1-different mice were given purified Lyt-2'
cells supplemented with donor BM . In this situation the recipients developed
typicalchronic GVHD, with most deaths occurring only after 1 mo ; thissyndrome
wasobserved with 1,000-fold variation in the dose of Lyt-2' cellsand with either
heavy (1,000 rad) or light (500 rad) irradiation of the hosts. Except for persistent
weight loss, symptoms ofGVHD were not usually apparent before 3-4wk after
transfer . At this stage the mice became overtly ill with prominent ruffled fur,
diarrhea, and increasing weight loss . Thereafter, the condition of the mice
deteriorated progressively over a 2-3-wk period . This syndrome of chronic
GVHD wasalmost invariably fatal; occasional mice madea partial recovery (more
prominent with older recipients), but these isolated survivors rarely regained full
health .
To account for the sudden, late onset ofthe symptoms which heralded chronic
GVHD,we initially considered the possibility that clinicalGVHD was precipitated
by interaction of Lyt-2' cells with newly derived L3T4' cells developing in the
host thymus . By responding to environmental antigens and releasing IL-2, we566
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speculated that these L3T4' cells augmented the effector function of Lyt-2'
cells and thus promoted a rapid wave of tissue damage. This scenario was not
supported by the finding that Tx and STx mice showed no significant difference
in their susceptibility to GVHD. Moreover, repeated injection ofanti-L3T4 mAb
had little or no effect in inhibiting GVHD. Collectively, these data suggest that,
as for short-term assays in vitro (11, 17), protracted in vivo responses of Lyt-2'
cells do not require exogenous help from L3T4+ cells (see also references 10,
12). Parenthetically, one might ask whether mice with GVHD are capable of
sustaining de novo formation of L3T4'' cells. On this point we have found only
negligible numbers (1-2%) of L3T' cells in spleen and LN of (non-Tx) mice
with chronic GVHD (unpublished data). This finding is not unexpected since
mice with chronic GVHD usually display marked thymic atrophy.
The protracted clinical course of chronic GVHD raises the question whether
the donor Lyt-2' cells attack the host continuously from the time ofinjection or,
alternatively, mount a briefattack which has delayed consequences. This second
possibility is not supported by the finding that hosts given a single injection of
anti-Thy-1 mAb at 3 wk after transfer of Lyt-2+ cells showed a much milder
pattern of GVHD (Fig. 4). The survival time of the recipients was considerably
prolonged and only 50% of the mice died. These data favor the view that the
donor Lyt-2' cells attack the host for a period exceeding 3 wk. Whether this
attack occurs continuously or in repeated waves, however, is unclear.
Although Lyt-2' cells appeared to be capable of eliciting GVHD in the
apparent absence ofL3T4' cells, supplementing Lyt-2' cells with small doses of
L3T4' cells led to a pattern ofacute GVHD with most deaths occurring at 2-3
wk after transfer; similar findings applied with mice given repeated injections of
rIL-2. These data suggest that, in contrast to chronic GVHD, the expression of
acute GVHD by Lyt-2' cells is under the strict control of L3T4' cells and/or
their products. It should be mentioned that the capacity of IL-2 to potentiate
GVHD has also been observed by two other groups (18, 19); these studies
involved transfer of unseparated lymphoid cells rather than purified Lyt-2' cells.
The capacity of L3T4' cells to augment GVHD mediated by Lyt-2' cells only
applied when L3T4' cells were injected in small doses. Thus when Lyt-2' cells
were transferred to class I-different mice together with very large doses of
L3T4+ cells, symptomsofGVHD were relatively mild andno mortality occurred.
This paradoxical finding raises the issue of the pathogenesis of GVHD . Since
GVHD is relatively mild in mice kept in a germ-free environment (20, 21), severe
forms of GVHD are presumably the end result of infection. In view of the
propensity of activated T cells to migrate to mucosal surfaces, e.g., the gut (22,
23), one can envisage that infectious organisms enter the body as the result of
local damage to the gut or respiratory tract; such damage might reflect direct
cell-mediated lympholysis or local release of toxic lymphokines, or both. The
notion that lethal forms ofGVHD are mainly the result ofinfection is in keeping
with the finding that GVHD is particularly severe in immunoincompetent hosts,
e.g., in irradiated mice (20). The obvious corollary here is that overcoming the
immune deficit in irradiated mice, e.g., by adding mature lymphoid cells lacking
host alloreactivity, would lessen the severity of GVHD. By this line of reasoning,
the protective effects of large doses of L3T4' cells are easily explained.SPRENT ET AL.
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Although the precise mechanism whereby L3T4' cells protect mice against
anti-class I GVHD is still unclear, the explanation we favor is that L3T4' cells
interact with B cells in the marrow suspension (or with the progeny ofthese cells)
and thus enable the host to make humoral responses against invading organisms.
Since marrow cells per se contain relatively few mature B cells, it would follow
that injection of a mixture of donor L3T4' cells and mature B cells, e.g., T-
depleted donor spleen, would augment the protective function of L3T4' cells.
Preliminary work has shown that this is indeed the case (our unpublished data).
Since L3T4' cells generally ignore class I differences (10, 11), the capacity of
L3T4' cells to protect mice against GVHD might be expected to apply only in
class I-different combinations. Thus, in class II-different hosts, the strong
reactivity of donor L3T4' cells against host alloantigens would tend to nullify
any protective (T helper) function of these cells. In fact, the sequel to this paper
will present evidence that, although small doses of L3T4' cells do cause 100%
mortality and rapid death in class II-different irradiated hosts, large doses of
L3T4' cells lead to only limited mortality. The protective function of L3T4'
cells thus seems to apply with either class I or class II disparity. The clinical
implications ofthis finding remain to be explored.
Summary
Detailed information was sought on the capacity of purified Lyt-2+ cells to
mediate lethal graft-versus-host disease (GVHD) directed to class I H-2 differ-
ences. When B6 Lyt-2' cells were transferred to irradiated class I-different (B6
X bml)F, mice, three different patterns of lethal GVHD were observed. First,
rapid death from hematopoietic failure occurred when Lyt-2' cells were trans-
ferred together with host-type marrow cells; this form of GVHD probably
reflected direct destruction of stem cells by Lyt-2' cytotoxic cells. Second, a
pattern of late-onset, chronic GVHD resulting in death only after 4-6 wk
occurred when Lyt-2+ cells were supplemented with donor marrow. This syn-
drome developed in the apparent absence of L3T4' cells and was observed with
either high or low doses of Lyt-2+ cells and with either light or heavy irradiation
of the host. Third, an acute form of GVHD resulted when Lyt-2+ cells plus
donor marrow cells were supplemented with exogenous help, i.e., by adding
small doses ofdonor L3T4' cells or injecting the hosts with rIL-2.
Although L3T4' cells potentiated GVHD when injected in small doses, sup-
plementing Lyt-2+ cells with large doses of L3T4' cells paradoxically led to
marked protection; symptoms of GVHD were mild and no deaths occurred .
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